drugset / Trial / NCT03988907

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

NCT03988907

Phase 1 Completed 35 enrolled Hoffmann-La Roche
Non-randomizedSequentialOpen-labelTreatment

Summary

This will be a Phase I, 2-part, open-label, non-randomized study to investigate the safety, tolerability, and pharmacokinetics (PK) of a multiple-dosing regimen of risdiplam (Part 1) and the effect of risdiplam on the PK of midazolam (Part 2) following oral administration in healthy adult male and female participants.

Timeline

Start
2019-06-18
Primary completion
2019-09-29
Completion
2019-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg Oral
Subject Risdiplam Small molecule 5 mg Oral